Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma

Plasma cell myeloma (PCM) is a clonal plasma cell neoplasm characterized by high morbidity and mortality. Recent advances in therapy starting in the mid-1990s have improved the outcome but the 5-year survival rate is only 50.2% [1 –3], indicating the need for continued development of novel therapies. Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) has achieved dramatic results in multiply relapsed and/or treatment resistant B-cell lymphoma and acute B-lymphoblastic leukemia [4,5] making it an attractive therap eutic approach for PCM.

Source: Leukemia Research - July 18, 2018 Category: Hematology Authors: Dalia A. Salem, Irina Maric, Constance M. Yuan, David J. Liewehr, David J. Venzon, James Kochenderfer, Maryalice Stetler-Stevenson Tags: Research paper Source Type: research